{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-016286","form_type":"8-K","ticker":"IMNN","cik":"0000749647","company_name":"Imunon, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.150140+00:00","generated_at":"2026-06-15T05:15:24.454772+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Imunon Q1 net loss narrows to $5.6M; cash runway into 2025; PLACCINE IND planned Q4 2023","bullets":["Net loss of $5.6M ($0.68/share) vs $10.5M ($1.82/share) in Q1 2022; operating expenses down 5% to $5.7M.","Cash and equivalents $37.3M at March 31, 2023; expects funding operations into 2025, plus $1.9M in NJ NOL sales.","Phase 1/2 trial of IMNN-001 + Avastin in advanced ovarian cancer opened for enrollment at MD Anderson and others.","Pre-IND consultation filed with FDA for PLACCINE COVID-19 booster; IND expected Q4 2023.","Collaborated with Wistar Institute to develop PLACCINE vaccines for infectious diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-016286","json":"https://secwatch.observer/filing/0001493152-23-016286.json","markdown":"https://secwatch.observer/filing/0001493152-23-016286.md","text":"https://secwatch.observer/filing/0001493152-23-016286.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/749647/000149315223016286/0001493152-23-016286-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/749647/000149315223016286/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T05:15:24.454772+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"226493829d7d4c1cc8ebab388d68dd71380a732b","claim":"Imunon, Inc. reported financial results for the three months ended March 31, 2023.","evidence_excerpt":"IMUNON, Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, today announced financial results for the three months ended March 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315223016286/0001493152-23-016286-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}